VITA 34 AG - Asset Resilience Ratio
VITA 34 AG (V3V) has an Asset Resilience Ratio of 1.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See V3V net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how VITA 34 AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VITA 34 AG (V3V) total assets.
Liquid Assets Composition Over Time
This chart breaks down VITA 34 AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore VITA 34 AG long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.76 Million | 1.1% |
| Total Liquid Assets | €1.76 Million | 1.10% |
Asset Resilience Insights
- Limited Liquidity: VITA 34 AG maintains only 1.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
VITA 34 AG Industry Peers by Asset Resilience Ratio
Compare VITA 34 AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ramsay Health Care Ltd
AU:RHC |
Medical Care Facilities | 3.49% |
|
Surgery Partners Inc
NASDAQ:SGRY |
Medical Care Facilities | 0.06% |
|
Chularat Hospital Public Company Limited
BK:CHG |
Medical Care Facilities | 1.18% |
|
Sarana Meditama Metropolitan
JK:SAME |
Medical Care Facilities | 0.00% |
|
Principal Capital Public Company Limited
BK:PRINC |
Medical Care Facilities | 1.23% |
|
Bait Bakfar Ltd
TA:BKFR |
Medical Care Facilities | 8.67% |
|
Regis Healthcare Ltd
AU:REG |
Medical Care Facilities | 2.29% |
|
Oceania Healthcare Ltd
AU:OCA |
Medical Care Facilities | 0.01% |
Annual Asset Resilience Ratio for VITA 34 AG (2007–2024)
The table below shows the annual Asset Resilience Ratio data for VITA 34 AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.07% | €1.64 Million ≈ $1.92 Million |
€152.74 Million ≈ $178.57 Million |
+0.02pp |
| 2023-12-31 | 1.05% | €1.66 Million ≈ $1.94 Million |
€158.36 Million ≈ $185.14 Million |
-10.98pp |
| 2022-12-31 | 12.03% | €18.23 Million ≈ $21.32 Million |
€151.51 Million ≈ $177.13 Million |
-7.84pp |
| 2021-12-31 | 19.88% | €35.37 Million ≈ $41.36 Million |
€177.95 Million ≈ $208.04 Million |
+1.89pp |
| 2020-12-31 | 17.99% | €10.52 Million ≈ $12.29 Million |
€58.46 Million ≈ $68.35 Million |
+2.91pp |
| 2019-12-31 | 15.08% | €9.21 Million ≈ $10.77 Million |
€61.10 Million ≈ $71.43 Million |
+3.12pp |
| 2018-12-31 | 11.96% | €7.09 Million ≈ $8.29 Million |
€59.32 Million ≈ $69.35 Million |
+4.92pp |
| 2017-12-31 | 7.04% | €4.36 Million ≈ $5.10 Million |
€61.96 Million ≈ $72.44 Million |
-0.92pp |
| 2016-12-31 | 7.95% | €3.45 Million ≈ $4.04 Million |
€43.42 Million ≈ $50.76 Million |
+5.58pp |
| 2015-12-31 | 2.38% | €1.04 Million ≈ $1.22 Million |
€43.78 Million ≈ $51.19 Million |
-1.71pp |
| 2010-12-31 | 4.09% | €1.50 Million ≈ $1.75 Million |
€36.69 Million ≈ $42.89 Million |
-2.33pp |
| 2009-12-31 | 6.42% | €2.00 Million ≈ $2.34 Million |
€31.15 Million ≈ $36.42 Million |
+3.53pp |
| 2008-12-31 | 2.89% | €876.00K ≈ $1.02 Million |
€30.31 Million ≈ $35.43 Million |
-3.16pp |
| 2007-12-31 | 6.05% | €1.95 Million ≈ $2.28 Million |
€32.26 Million ≈ $37.71 Million |
-- |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more